Condition: Focal Segmental Glomerulosclerosis · Sponsor: Yale University
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
This description comes directly from the study's public registry record.
Madhav C Menon, MD · 20373734507 · madhav.menon@yale.edu
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Mount Sinai Hospital | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06090227